Amphastar signs exclusive BAQSIMI distribution deal in Greater China with related party
Amphastar entered a Distribution Agreement effective October 21, 2025, appointing Nanjing Chengong Pharmaceutical as exclusive distributor of BAQSIMI in Mainland China, Taiwan, Hong Kong, and Macau. The filing says the deal's total revenue to Amphastar cannot be determined yet, because per-unit net revenues may vary, and it is a related party transaction with a company controlled by the CEO and Chairman's family.
Key points
- Agreement effective October 21, 2025, with a ten-year term; either party may terminate without cause after the fourth Contract Year.
- Chengong must obtain regulatory approvals in the Region, perform post-marketing clinical trials, and meet minimum purchase amounts per contract year.
- Amphastar and Chengong will share profits on earnings above a floor price per unit, based on Chengong's per-unit net revenue.
- Dr. Jack Zhang and Dr. Mary Luo, with certain family members, own a majority of Hanxin, Chengong's parent. The independent Audit Committee approved the agreement.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 24, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.